The FDA announced Emergency Use Authorization of C

The FDA announced Emergency Use Authorization of Convalescent Plasma for CV19. Patients under 80 that get the treatment early in the virus show a 35% improvement in mortality rate based on initial statistical evaluation. As stated this was NOT a formal FDA study but it is still excellent news as there is worldwide demand for effective CV19 treatments. Gilead’s Remdesivir had been the only Emergency Use Authorized treatment available and data to date has demonstrated a reduction in hospital time from 15 days to 11 days but no statistically relevant improvement in mortality.

Mark Meadows on Sunday morning mentioned that today’s announcement will be one of several announcements that will take place over the next few weeks in regards to CV19 treatments. Additional treatments that I believe MAY be approved for Emergency Use in the coming weeks MAY include CytoDyn’s Leronlimab and Regeneron’s REGN-COV2 antibody cocktail.

All the above treatments are showing some promise and are of the utmost importance. With that said, there is NO TREATMENT that I am aware of that in totality kills the CV19 on contact, prevents the viral replication, modulates the inflammatory response and has anti-microbial and antibiotic properties like IPIX’s Brilacidin. If Brilacidin can prove to be as effective in CV19 human trials as it has shown in lab testing I believe it will leap to the top of the CV19 treatments. The next few weeks should be exciting.